Omidenepag | CAS#1187451-41-7 | prostaglandin receptor agonist

MedKoo Cat#: 319587 | Name: Omidenepag

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Omidenepag, also known as UR-7276, is a prostaglandin receptor agonist. Omidenepag is a a novel E prostanoid receptor 2 (EP2) agonist. Omidenepag acts on not only the uveoscleral pathway but also the conventional pathway, unlike F prostanoid (FP) receptor agonists.

Chemical Structure

Omidenepag

CAS#1187451-41-7

Theoretical Analysis

MedKoo Cat#: 319587

Name: Omidenepag

CAS#: 1187451-41-7

Chemical Formula: C23H22N6O4S

Exact Mass: 478.1423

Molecular Weight: 478.53

Elemental Analysis: C, 57.73; H, 4.63; N, 17.56; O, 13.37; S, 6.70

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 550.00	2 Weeks
10mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Omidenepag; UR-7276; UR 7276; UR7276;

IUPAC/Chemical Name

(6-((N-(4-(1H-pyrazol-1-yl)benzyl)pyridine-3-sulfonamido)methyl)pyridin-2-yl)glycine

InChi Key

YHGSTSNEOJUIRN-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H22N6O4S/c30-23(31)15-25-22-6-1-4-19(27-22)17-28(34(32,33)21-5-2-11-24-14-21)16-18-7-9-20(10-8-18)29-13-3-12-26-29/h1-14H,15-17H2,(H,25,27)(H,30,31)

SMILES Code

O=S(N(CC1=NC(NCC(O)=O)=CC=C1)CC2=CC=C(N3C=CC=N3)C=C2)(C4=CN=CC=C4)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 478.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wang TH, Aung T, Lu DW, George R, Senthil S, Lu F, Odani-Kawabata N, Park KH. Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial. Clin Ophthalmol. 2024 Jul 16;18:2093-2106. doi: 10.2147/OPTH.S465369. PMID: 39051019; PMCID: PMC11268578. 2: Horikiri K, Taketomi Y, Kondo K, Yamasoba T, Murakami M. Activation of the PGE2-EP2 pathway as a potential drug target for treating eosinophilic rhinosinusitis. Front Immunol. 2024 Jul 1;15:1409458. doi: 10.3389/fimmu.2024.1409458. PMID: 39015572; PMCID: PMC11250097. 3: Nakamura N, Honjo M, Yamagishi-Kimura R, Sakata R, Watanabe S, Aihara M. Neuroprotective effect of omidenepag on excitotoxic retinal ganglion cell death regulating COX-2-EP2-cAMP-PKA/Epac pathway via Neuron-Glia interaction. Neuroscience. 2024 Aug 16;553:145-159. doi: 10.1016/j.neuroscience.2024.07.006. Epub 2024 Jul 9. PMID: 38992567. 4: Inoue K, Shiokawa M, Kunimatsu-Sanuki S, Kang J, Uraki T, Tomita G, Ishida K. Three-year efficacy and safety of omidenepag isopropyl in patients with normal tension glaucoma. Jpn J Ophthalmol. 2024 May;68(3):206-210. doi: 10.1007/s10384-024-01052-8. Epub 2024 Apr 8. PMID: 38587788. 5: Bacharach J, Brubaker JW, Evans DG, Lu F, Odani-Kawabata N, Yamabe T, Wirta DL. Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3). Am J Ophthalmol. 2024 Jul;263:23-34. doi: 10.1016/j.ajo.2024.02.010. Epub 2024 Feb 21. PMID: 38395329. 6: Sharif NA. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor- selective agonist ocular hypotensive drug. Curr Opin Pharmacol. 2024 Feb;74:102426. doi: 10.1016/j.coph.2023.102426. Epub 2024 Jan 1. PMID: 38168596. 7: Benitez B, Anter AM, Arcuri J, Bhattacharya SK. Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review. Curr Opin Pharmacol. 2024 Feb;74:102424. doi: 10.1016/j.coph.2023.102424. Epub 2023 Dec 30. PMID: 38160646; PMCID: PMC10922870. 8: Gettman L. New Drugs: Faricimab-svoa (Vabysmo™) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti™) for Glaucoma and Ocular Hypertension. Sr Care Pharm. 2023 Dec 1;38(12):497-500. doi: 10.4140/TCP.n.2023.497. PMID: 38041224. 9: Nakamura N, Honjo M, Yamagishi R, Sakata R, Watanabe S, Aihara M. Synergic effects of EP2 and FP receptors co-activation on Blood-Retinal Barrier and Microglia. Exp Eye Res. 2023 Dec;237:109691. doi: 10.1016/j.exer.2023.109691. Epub 2023 Oct 24. PMID: 37884204. 10: Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A. Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study. J Glaucoma. 2023 Dec 1;32(12):999-1005. doi: 10.1097/IJG.0000000000002321. Epub 2023 Oct 17. PMID: 37853676; PMCID: PMC10681282. 11: Kuo HT, Yeh CY, Hsu AY, Ho JH, Lin CJ, Tsai YY. Clinical Efficacy of Omidenepag Isopropyl for Primary Open-Angle Glaucoma, Normal Tension Glaucoma, or Ocular Hypertension: A Meta-Analysis. J Ocul Pharmacol Ther. 2023 Dec;39(10):705-715. doi: 10.1089/jop.2023.0058. Epub 2023 Aug 9. PMID: 37579061. 12: Bae BJ, Kang EM, Lee SY. Cystoid macular edema associated with omidenepag isopropyl in a phakic eye with an implantable collamer lens: a case report. BMC Ophthalmol. 2023 Jul 26;23(1):334. doi: 10.1186/s12886-023-03091-0. PMID: 37495978; PMCID: PMC10373310. 13: Liu M, Honjo M, Yamagishi R, Aihara M. Effects of Brimonidine, Omidenepag Isopropyl, and Ripasudil Ophthalmic Solutions to Protect against H2O2-Induced Oxidative Stress in Human Trabecular Meshwork Cells. Curr Eye Res. 2023 Nov;48(11):1014-1025. doi: 10.1080/02713683.2023.2235892. Epub 2023 Jul 19. PMID: 37466387. 14: Tsugeno Y, Sato T, Watanabe M, Furuhashi M, Ohguro H. Prostanoid FP and EP2 Receptor Agonists Induce Epithelial and Subepithelial Fibrogenetic Changes in Human Conjunctival Fibroblasts in Different Manners. J Ocul Pharmacol Ther. 2023 Jul;39(6):404-414. doi: 10.1089/jop.2023.0011. PMID: 37459581. 15: Sharif NA. Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients. Pharmaceuticals (Basel). 2023 May 26;16(6):791. doi: 10.3390/ph16060791. PMID: 37375739; PMCID: PMC10304251. 16: Hikage F, Watanabe M, Sato T, Umetsu A, Tsugeno Y, Furuhashi M, Ohguro H. Simultaneous Effects of a Selective EP2 Agonist, Omidenepag, and a Rho- Associated Coiled-Coil Containing Protein Kinase Inhibitor, Ripasudil, on Human Orbital Fibroblasts. J Ocul Pharmacol Ther. 2023 Sep;39(7):439-448. doi: 10.1089/jop.2023.0025. Epub 2023 Jun 23. PMID: 37352418. 17: Sharif NA. Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment and prevent blindness. Exp Eye Res. 2023 Jul;232:109444. doi: 10.1016/j.exer.2023.109444. Epub 2023 Mar 21. PMID: 36958427. 18: Sharif NA, Odani-Kawabata N, Lu F, Pinchuk L. FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma. Exp Eye Res. 2023 Apr;229:109415. doi: 10.1016/j.exer.2023.109415. Epub 2023 Feb 18. PMID: 36803996. 19: Lee SH, Lee WJ, Kim KW, Jeong JH, Park IK, Chun YS. Influence of 0.002% Omidenepag Isopropyl on Intraocular Pressure and the Cornea in Normal Tension Glaucoma. J Glaucoma. 2023 Apr 1;32(4):245-251. doi: 10.1097/IJG.0000000000002167. Epub 2022 Dec 21. PMID: 36729067. 20: Kumon M, Fuwa M, Shimazaki A, Odani-Kawabata N, Iwamura R, Yoneda K, Kato M. Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells. PLoS One. 2023 Jan 11;18(1):e0280331. doi: 10.1371/journal.pone.0280331. PMID: 36630412; PMCID: PMC9833537.